The Pharmaceutical Management Agency of New Zealand, PHARMAC, has announced reaching agreement with US drug major Eli Lilly (NYSE: LLY) to approve listing of its drug Effient (prasugrel) for use by patients allergic to clopidogrel, the blockbuster blood thinner Plavix from Sanofi.
This was the subject of a consultation letter dated February 20, 2012. In summary, the effect of the decision is that Effient will be fully funded from April 1, 2012, for clopidogrel-allergic patients who have undergone percutaneous coronary intervention (PCI).
Details of the proposal
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze